Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab versus placebo in rheumatoid arthritis after inadequate response to TNF inhibitor therapy
2015-005308-27Phase 3Completed
- Sponsor
- R-Pharm
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olokizumab in rheumatoid arthritis (RA) (3 arms), sponsored by R-Pharm. Primary endpoint: ACR20 response at Week 14. Started Apr 2016; status: completed.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-005308-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005308-27.